Venous Leg Ulcer Clinical Trial
— EVRAOfficial title:
A Randomised Clinical Trial to Compare Early Versus Delayed Endovenous Treatment of Superficial Venous Reflux in Patients With Chronic Venous Ulceration
Verified date | July 2019 |
Source | Imperial College London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The EVRA study evaluates the effects of early endovenous ablation on ulcer healing in patients with chronic venous ulceration. Half the patients are randomised to receive early endovenous ablation (within 2 weeks) and half to standard care
Status | Completed |
Enrollment | 450 |
Est. completion date | March 31, 2019 |
Est. primary completion date | March 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Current leg ulceration of greater than 6 weeks, but less than 6 months duration - Able to give informed consent to participate in the study after reading the patient information documentation - Patient age > 18 years - Ankle Brachial Pressure Index (ABPI) = 0.8 - Superficial venous disease on colour duplex assessment deemed to be significant enough to warrant ablation by the treating clinician (either primary or recurrent venous reflux) Exclusion Criteria: - Presence of deep venous occlusive disease or other conditions precluding superficial venous intervention (at the discretion of local research team) - Patients who are unable to tolerate any multilayer compression bandaging / stockings will be excluded. However, concordance with compression therapy can be variable for patients at different times. Patients who are generally compliant with compression, but unable to tolerate the bandages for short periods will still be eligible to inclusion. A period of non-compliance with compression bandages will not be considered a protocol violation, but a normal variation within the spectrum of 'standard therapy'. - Inability of the patient to receive prompt endovenous intervention by recruiting centre - Pregnancy (female participants of reproductive age will be eligible for inclusion in the study, subject to a negative pregnancy test prior to randomisation) - Leg ulcer of non-venous aetiology (as assessed by responsible clinician) - Patient deemed to require skin grafting |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Imperial College London | London |
Lead Sponsor | Collaborator |
---|---|
Imperial College London | Universidad de Granada, University of Birmingham, University of Manchester, University of Warwick |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to ulcer healing | For the purposes of this study, ulcer healing is defined as complete re-epithelialisation of all ulceration on the randomised (reference) leg in the absence of a scab (eschar) with no dressing required. | time from date of randomisation to date of healing within the 12 month study period | |
Secondary | Ulcer Healing Rate | Healing rate will be reported at 24 weeks in addition to time to ulcer healing to allow comparison with other published studies | 24 weeks & time to ulcer healing within the 12 month study period | |
Secondary | Ulcer recurrence / Ulcer Free Time | Will be calculated up to 1 year for each study arm and with the extension, up to 5 years (median approximately 3.7 years). This will allow a very practical and easily understood assessment of the clinical difference between the 2 arms of the study. This will also allow comparison with other studies that have reported this outcome. In order to facilitate accurate calculation of reoccurrence / ulcer free time, clinical follow up will be continued after ulcer healing up to 1 year after randomisation. | Up to 12 months (and with the extension, up to 5 years (median approximately 3.7 years)) | |
Secondary | Quality Of Life Questionnaire | Disease specific (AVVQ) quality of life | 6 weeks post randomisation, 6 months, 12 months and at one time point between October 2018 and March 2019 | |
Secondary | Quality Of Life Questionnaire | Generic (SF36) quality of life assessment | 6 weeks post randomisation, 6 months, 12 months and at one time point between October 2018 and March 2019 | |
Secondary | Quality Of Life Questionnaire | Generic (EQ5D )quality of life assessment | 6 weeks post randomisation, 6 months, 12 months and at one time point between October 2018 and March 2019 | |
Secondary | Health Economic Assessment | A within-RCT cost effectiveness analysis will be carried out based on the data collected in the trial, Resource use items in hospital and community care related to the treatment of venous ulceration or complications will be recorded for each patient at each follow-up. Resource use will be multiplied by UK unit costs obtained from published literature, HRG costs, and manufacturers' list prices to calculate overall costs. A standard tariff will be applied for each bandage change. Utilities (QALYs) will be calculated from the EQ-5D questionnaire administered to patients | Baseline, 6 weeks, 6 months, 12 months | |
Secondary | Clinical Success - Presence of residual / recurrent varicose veins | The presence of residual / recurrent varicose veins remaining on the venous duplex | at 6 weeks | |
Secondary | Clinical Success - VCSS | The Venous Clinical Severity Score (VCSS) | at 6 weeks | |
Secondary | Clinical Success - Complications | Incidence of complications related to the endovenous intervention | up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03903692 -
A Comparative Evaluation of a MPS Dressing and a CMC Dressing on Subjects With Lower Extremity Venous Ulcers
|
N/A | |
Completed |
NCT03257254 -
Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
|
||
Recruiting |
NCT03666754 -
Early Glue Saphenous Vein Ablation With Compression Versus Compression Alone in the Healing of the Venous Ulcer
|
N/A | |
Withdrawn |
NCT02912858 -
Intermittent Pneumatic Compression of the Foot vs Geko Plus R-2 Neuromuscular Electrostimulation Device in Venous Leg Ulcer Patients
|
N/A | |
Completed |
NCT02482038 -
Geko Venous Leg Ulcer Study
|
N/A | |
Completed |
NCT02652572 -
Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulcers
|
Phase 1 | |
Unknown status |
NCT01658618 -
Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer
|
N/A | |
Completed |
NCT05646121 -
Suprasorb® A + Ag in the Treatment of Wounds at Risk of Infection and Infected Wounds
|
||
Completed |
NCT03077165 -
Dose-response Relationship Study of S42909 on Leg Ulcer Healing
|
Phase 2 | |
Completed |
NCT04461132 -
The Effect of Manual Lymphatic Drainage
|
N/A | |
Completed |
NCT05974982 -
Treatment Outcome of Autologous PRP Versus Conventional Therapy Among Patients With Chronic Venous Leg Ulcers
|
Phase 1 | |
Completed |
NCT04011371 -
Cyanoacrylate Closure for Treatment of Venous Leg Ulcers
|
N/A | |
Not yet recruiting |
NCT03543007 -
Evaluating the Safety and Efficacy of GrafixPLâ„¢PRIME for the Treatment of Chronic Venous Leg Ulcers
|
N/A | |
Recruiting |
NCT05588583 -
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
|
N/A | |
Not yet recruiting |
NCT04613687 -
Efficacy and Safety of a New Compression System URGO BD001 in the Treatment of VLU (FREEDOM)
|
N/A | |
Recruiting |
NCT05549609 -
A Study of XSTEM-VLU in Patients With Difficult-to-heal Venous Leg Ulcers
|
Phase 1/Phase 2 | |
Recruiting |
NCT05409976 -
The GORE® VIAFORT Vascular Stent IVC Study
|
N/A | |
Not yet recruiting |
NCT05089890 -
Clinical Investigation of Sorbact® Dressings
|
N/A | |
Not yet recruiting |
NCT03670329 -
Management of Infection Risk in Non-comparative Trial (MINT)
|
N/A | |
Completed |
NCT02921750 -
Investigation to Evaluate the Efficacy and Safety of Exufiber Versus Aquacel Extra in Moderately or Strongly Exuding Venous and Mixed Ulcers of Predominantly Venous Origin
|
N/A |